The mice are not you. It is worth saying out loud before some clinic on Orchard Road turns a mouse study into a bottle, which on the current timetable takes about a month.
Here is the study, flat. A USC lab led by Valter Longo fed 20-month-old mice one of four diets: a standard chow, a Western diet loaded with fat and sugar, a low-carb ketogenic diet, and a low-protein, plant-and-fish diet carrying just enough of the amino acid methionine. The mice on the last one, which the paper calls the LDMM, ate more food than any other group, took in the same calories, and still lost body fat while holding on to lean muscle. They were less frail. They spent more of their lives in good health. Growth hormone, GLP-1 and FGF21, three of the signals that regulate metabolism and ageing, all moved in the right direction. Longo’s own line is that the result “challenges the dogma that calorie reduction is necessary to lose weight.”
The lever was a single amino acid, dialled to a window. Too little methionine and the mice grew frail; too much and the whole benefit vanished. Methionine is ordinary. It is concentrated in the loaded proteins, red meat, eggs, dairy, and it runs low in the plants and fish that the traditional Italian and Okinawan tables are built from. What the lab built was an old plate, the one a few hundred million people around the Mediterranean have eaten for centuries with no branding attached.
Methionine restriction has circled ageing research since 1993, when Orentreich’s group first cut it in rats and watched median lifespan rise about 30 percent, and every few years it comes back cleaner. Grade this one honestly. It is Level 1 evidence in mice, and Maura Fanti, the first author, is careful to say the pathways are regulated differently in humans. What makes it worth a column is that the human epidemiology already rhymes. In the same paper, across more than 200,000 people, those eating the most animal protein carried twice the rate of type 2 diabetes and more obesity than the low-intake group, on fewer calories.
The longevity industry keeps bottling the molecule the evidence keeps finding in the meal.
The longevity industry keeps bottling the molecule the evidence keeps finding in the meal. A methionine-blocking supplement will sit on a shelf in Singapore, a few hundred dollars a bottle, long before any controlled human trial reads out. The molecule is what you can sell; the plate is what did the work. It is the same trick the field ran from resveratrol to NMN: isolate the active fraction, price it, and skip the boring thing it was pulled out of.
The boring thing, for this region, is provenance. Singapore imports more than 90 percent of its food from 187 countries, and the state’s own answer, the 30-by-30 push, is a bet on growing more of it closer to home. As affluent Singapore eats toward cleaner, closer, less industrial, the businesses that win the next decade are the ones that can show where the fish was landed and what the plant was fed. A low-methionine diet, described in a journal, is a demand signal for exactly that. A plate is legible. A capsule asks you to take its word.
The molecule is what you can sell; the plate is what did the work.
I stopped seeing patients to write, so take this as a writer’s read and not a prescription: one mouse study changes nothing about what belongs on your table tomorrow. The mechanism under it, though, is thirty years old, unpatented, and unglamorous, and it keeps pointing at the same dinner. More plants, some fish, less of the loaded protein.1
The mice needed a lab to arrive there. The Mediterranean got there without one.
Footnotes
-
The supplement version has a tell. A capsule of methionine-restriction mimetic asks you to believe the lab isolated the one thing that mattered from a diet whose whole point, in every study that has ever worked, was the balance across the plate. ↩